It has been shown that miR-223-3p, when combined with serum AFP, has a sensitivity of about 85% for early-stage cancer and 100% for detecting intermediate and advanced HCC when the combined assay is applied in comparison with the non-HCC group and healthy controls (131). This evidence concerns the gene AFP and hepatocellular carcinoma.